Objective: Limited data is available to guide non-surgical management of Stage T4 larynx and hypopharynx cancer patients who have inoperable disease or refuse surgery. We aim to review the nonoperative management of T4 laryngeal and hypopharyngeal cancer and report the long-term therapeutic and functional outcomes.Methods: We reviewed the nonoperative management of T4 laryngeal (n = 44) and hypopharyngeal (n = 53) cancer from 1997 to 2015 and performed a univariate analysis (UVA).Results: The 2-/5-year OS rates were 73%/38% for larynx patients and 52%/29% for hypopharynx patients. Locoregional failure (LRF) occurred in 25% and 19% of larynx and hypopharynx patients, respectively. On UVA of the larynx subset, N3 nodal status and non-intensity-modulated radiation therapy were negatively associated with OS; treatment with radiation therapy alone impacted disease-free survival; and age >70 was associated with LRF. On UVA of the hypopharynx subset, only T4b status significantly impacted OS. In the larynx and hypopharynx groups, 68% and 85% received a percutaneous endoscopic gastrostomy (PEG) tube and 32% and 40% received a tracheostomy tube, respectively. At the last follow-up visit, 66% of our larynx cohort had neither tracheostomy or PEG placed and 40% of our hypopharynx cohort had neither. Conclusion:We report better than previously noted outcomes among T4 larynx and hypopharynx patients who have unresectable disease or refuse surgery.
Background: The aim of this phase II clinical study was to evaluate three-weekly docetaxel plus prednisolone as firstline chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC). Materials and Methods: Thirty five metastatic HRPC patients were treated with docetaxel 70 mg/m2 on Day 1, every 3 weeks plus oral prednisolone 5 mg twice daily at Clinical Oncology Departments, Tanta, Mansoura and Menofia University Hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate. Secondary endpoints were assessment of PSA response rate, overall survival rate and the time to disease progression. Results: In 35 patients with metastatic HRPC, the median number of cycles administered was 6 cycles. Partial response was observed in 15 patients (42.9%) with evaluable measurable disease. Median survival from protocol entry was 12 months. Median time to disease progression was 9 months. Prostate-specific antigen (PSA) declined ≥50% in 9 patients (25.7%). The most common grade 34/ toxicity associated with studied protocol was neutropenia (85.7%). Conclusions: When given with prednisolone, treatment with docetaxel every three weeks lead to improved survival and response rates with accepted tolerability.
Objective: To examine the C-X-C Motif Chemokine Receptor 1 expression in breast cancer tissues prior to neo-adjuvant chemotherapy, and its relationship to neo-adjuvant chemotherapy effectiveness and other prognostic variables.Method: The prospective study was conducted at Kafrelsheikh University Hospital, Egypt, from November 2018 to March 2021, and comprised patients with recent histopathologically proven breast cancer cases eligible for chemotherapy. Paraffin blocks of tumour specimens were stained by immunohistochemical stain using concentrating rabbit anti-human C-X-C Motif Chemokine Receptor 1 polyclonal antibody kits. C-X-C Motif Chemokine Receptor 1 expression was classified into low and high categories. Patients were followed for 2 years for treatment response, disease recurrence and mortality. Data was analysed using SPSS 25.Results: Of the 100 females with mean age 50.2±12.1 years, 52(52%) had their left side affected, while 48(48%) had their right side affected. There were 52(52%) cases with mean age 49.2±12.9 years having high C-X-C Motif Chemokine Receptor 1 expresssion, while 48(48%) with mean age 51.4±11.2 years had low expression. There was a significant association between high expression and advanced tumour grade, advanced tumour stage, higher frequency of triple negative breast cancer and higher frequency of Ki-67-positive cancers (p<0.05). Patients with high C-X-C Motif Chemokine Receptor 1 expression had significantly lower frequency of complete pathological response when compared with patients with low expression (p<0.001). Patients with high expression had higher frequency of recurrence, shorter disease-free survival, higher mortality and shorter overall survival, but the difference was notsignificant (p>0.05). Multivariate logistic regression analysis identified triple negative hormonal status (p=0.031) and high baseline C-X-C Motif Chemokine Receptor 1 expression (p<0.001) as significant predictors of complete pathological response.Conclusions: There was found to be a link between baseline C-X-C Motif Chemokine Receptor 1 expression in breast cancer tissues and pathological response to neoadjuvant therapy in breast cancer patients. Keywords: Neoadjuvant therapy, Prognosis, Ki67 proliferation marker, Paraffin, Immunohistochemistry, Breast neoplasms, Chemokines.
Purpose: Sorafenib is an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor and Raf with demonstrated efficacy as first-line therapy for patients with inoperable hepatocellular carcinoma (HCC). We reported the preliminary results of this treatment to evaluate its safety, tolerability, and efficacy in patients with inoperable HCC. Patients and Methods:Patients with inoperable HCC and a Karnofsky performance status (KPS) of ≥70, Child-Pugh (CP) score of A or B, an elevated alphafetoprotein (AFP) level and adequate hematologic, renal and hepatic functions; were enrolled. No Prior therapy was permitted. The regimen was sorafenib at a dose of 400 mg bid, given 7 days per week. Treatment was maintained until disease progression or unacceptable toxicity.Results: Twenty one patients with a median age of 53 years (range, 39-73 years) were accrued KSA. Previously, no Prior therapy was permitted. All patients who were entered on the study were assessable for toxicity and response of sorafenib. There were 2 clinical responses (9.5%) and another 8 (38.1%) had stable disease. Disease control rate was 47.6%. No Grade 3-4 hematologic toxicities were recorded. The most common grade 3-4 non-hematological toxicities were fatigue in 3 patients (14.3%), hand-foot skin reaction (HFS) in 2 patients (9.5%) and Diarrhea in 2 patients (9.5%).The estimated median progression-free and median overall survival times were 4 and 9 months, respectively, and the 1-year overall survival rate was 38.1%. There was no treatment-related death. Conclusion:The results of this study suggested that, in the population with inoperable HCC, daily sorafenib regimen had good clinical activity with an acceptable toxicity.
Objective: The To distinguish between basal and non-basal subtypes of triple-negative breast cancers based on epidermal growth factor receptor and cytokeratin 5/6, and to establish the association of the diagnosis with clinicopathological parameters and survival rates.Methods: The retrospective study was conducted at the Clinical Oncology and Nuclear Medicine Department of Kafrelsheikh University Hospital and Tanta University Hospital, Egypt, and comprised medical records from January 2014 to December 2018 related to cases with histopathologically proven triple-negative breast cancer who had been treated and followed up for at least 5 years. The cases had been evaluated using immunohistochemistry for epidermal growth factor receptor and Cytokeratin 5/6 expression. Data related to prognostic factors, overall survival and diseasefree survival was retrieved. Data was analysed using SPSS 21.Results: There were 100 patients with median age 50 years (inter-quartile range: 35-55.25 years; range: 22-69 years). There were 58(58%) pre-menopausal subjects, 15(15%) had positive family history, and 68(68%) had tumour size T2. Basal markers were noted in 74(74%) patients. Basal subtype was significantly more common in patients aged <50 years at diagnosis, premenopausal women, patients with positive nodal status, those with grade III tumours, and patients with Ki67 proliferation marker >20% (p<0.05). Tumour size, histological subtypes and lympho-vascular invasion were not significantly different between the groups (p>0.05). The basal subtype had worse disease-free survival and overall survival rates (p<0.05).Conclusion: Triple-negative breast cancer patients who expressed epidermal growth factor receptor and/or cytokeratin 5/6 were found to have poor findings, with worse disease-free survival and overall survival.Keywords: Breast neoplasms, Ki67 antigen, EGFR Receptors, Oncology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.